The short answer
Do not add kratom to selinexor without the cancer team’s review. Selinexor can cause neurological symptoms, and a sedating supplement may make alertness or balance harder to manage; the exact combined effect has not been measured.
What this answer covers
Oral selinexor with kratom preparations. Leaf alkaloid content and concentrated products differ.
- Supplement or preparation
- Mitragyna speciosa
- Medication ingredient
- selinexor
Check the prescribed treatment
This review concerns oral selinexor. Its schedule and combination medicines depend on the cancer treatment plan. The drug can cause low platelets, dizziness or confusion, and other medicines and hydration status may contribute. Keep the complete regimen and monitoring plan under the cancer team’s direction.
Why alertness matters
Selinexor can cause dizziness, confusion and other neurological symptoms. Its product information advises reviewing other medicines and hydration to avoid worsening dizziness or mental-status changes, and using precautions against falls. Report new symptoms rather than assuming they are an expected supplement effect.
What is known about the supplement
Kratom can produce stimulant effects as well as opioid-like or sedating effects. Poison-center reports include serious outcomes, especially with multiple substances, but those selected reports do not measure the risk of selinexor co-use or represent all users.
Review the cause of sleep or pain symptoms
Show the team the exact product and dose, including alcohol, sleep aids, pain medicines and anti-nausea medicines. Do not drive when dizzy or confused, and seek prompt assessment for marked changes in alertness. A dose gap has not been shown to prevent this concern, and cancer treatment should not be adjusted without the team.
Evidence and practical considerations
Side effects & toxicity
A conditional alertness/fall-risk precaution is supported, without proving a specific combined CNS-depression rate.
- Exact scope
- Oral selinexor with kratom preparations. Leaf alkaloid content and concentrated products differ. with RxNorm 2178390 IN selinexor. Exact current oral product: XPOVIO oral selinexor tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact co-use study; conditional neurological precaution, not established respiratory depression or a dose-specific additive rate. Poison-center selection/co-exposures limit attribution.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Thrombocytopenia and neurological toxicity; clinical CYP3A inhibitor and inducer PK null results.
How this applies: RxNorm 2178390 IN selinexor. Exact current oral product: XPOVIO oral selinexor tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Original official botanical guidance
nccih.nih.gov · Source check Sep 11, 2026
Population: Kratom users.
Can have stimulant or opioid-like/sedative effects including confusion.
How this applies: Conditional neurological safety concern.
No selinexor trial or same-dose equivalence across leaves/extracts.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 1807 poison-center-reported exposures, 2011–2017.
Serious outcomes occurred; multiple-substance reports had greater odds of severe outcomes.
How this applies: Exact preparation/population/endpoints only; applicability to selinexor independently assessed.
Abstract-only selected poison reports, not incidence among users or selinexor-specific causation; stimulant effects also common.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
selinexor is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: 51b18e2ee8541297
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.